Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.

摘要: BJU Int 2012; 110: E381–E386. Objectives: To assess the efficacy of desmopressin plus oxybutynin and compare two starting dosages (120 240 g) in a randomized, double-blinded, placebo-controlled trial for children with monosymptomatic nocturnal enuresis (MNE) resistant to desmopressin. The predictive factors MNE responsive combination therapy were also evaluated. Patients Methods: Our sample included 206 patients aged between 6 13 (mean age 10.6 2.9 years), 117 males. All required have MNE. randomly divided into groups: first group was given oral melt 120 g second g, 2 weeks. who had experienced failure treatment sublingually administered alone either 5 mg or placebo double-blinded 4 As factors, bladder volume wall thickness index, polyuria voiding latency considered. Results: There no significant difference terms response. showed higher rate full partial responses (45% success) compared (17% success), P 0.01. responders combined significantly lower index than other patients. Conclusions: findings highlight that anticholinergic agents may play an important role subset restricted capacity thickened wall. Ultrasonographymeasured variables can provide useful clues Predictive help differentiate subtypes guide clinical management primary enuresis. Editorial Comment: This study reviews MNE, their different doses oxybutynin. Despite seemingly homogeneous presenting symptoms, responded best greater urine production. Those indices (defined by maximum measured mean thickness). provides algorithm helps large pediatric cases we see, which at glance appear but fact represent groups, ie 1 nighttime production tendency toward overactive bladder.